drugset
drugset / Trial / NCT03284931

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

NCT03284931 ↗

Phase 1 Completed 45 enrolled Biogen
RandomizedCrossoverTriple-blindTreatment

Summary

This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.

Timeline

Start
2017-09-14
Primary completion
2017-12-04
Completion
2017-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Zuranolone Small molecule — —

Indications

No indication recorded.